Journals / Turkish Journal of Gastroenterology / 2004 / Cilt: 15 - Sayı: 2

Karaciğer sirozunda nitrik oksit ve renal fonksiyonlar

Nitric oxide and renal functions in liver cirrhosis

Pages
73–76
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We also showed that this increase negatively affects the renal tubular and glomerular functions.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Nitric oxide, a potent vasodilating agent, has been proposed to play a role in pathogenesis of ascites and hepatorenal syndrome.
📊
Key Findings & Data:Methods: The study population included 38 subjects: 14 patients with chronic hepatitis, 11 with preascitic cirrhosis and 13 with ascitic cirrhosis.
💡
Conclusion & Impact:We also showed that this increase negatively affects the renal tubular and glomerular functions.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Karaciğer sirozu · Nitrik oksit · Nitrik-oksit sentaz

Abstract

Nitric oxide, a potent vasodilating agent, has been proposed to play a role in pathogenesis of ascites and hepatorenal syndrome. The aim of this study was to evaluate the interaction between the plasma nitric oxide, nitric oxide synthetase levels and renal functions in patients with different degrees of chronic liver disease. Methods: The study population included 38 subjects: 14 patients with chronic hepatitis, 11 with preascitic cirrhosis and 13 with ascitic cirrhosis. Nitric oxide and nitric oxide synthetase were determined by colorometric assay. We calculated glomerular filtration rate and fractional sodium excretion. Results: Nitric oxide levels in groups were as follows: 79.28±24.86, 99.03±21.31, 197.05±49.61 µm, respectively. Nitric oxide synthetase levels were 2.64±0.56, 3.64±0.89, 7.75±2.46 µmol/L/sec, respectively. Nitric oxide and nitric oxide synthetase levels in the ascitic cirrhotic group were significantly higher than in the others (p<0.05). When glomerular filtration rates were compared, the only significant difference was determined between the groups with chronic hepatitis and ascitic cirrhosis (92.31±25.21, 48.46±16.45, p<0.05). Fractional sodium excretion was significantly increased in the ascitic cirrhotic group (4.42±2.76, p<0.05). Conclusions: Nitric oxide and nitric oxide synthetase increased with progression of liver disease, especially in ascitic cirrhosis. We also showed that this increase negatively affects the renal tubular and glomerular functions.

Özet

Nitrik oksit, potansiyel bir vazodilatatör ajan olup asit ve hepatorenal sendromun patogenezinde rol oynadığı düşünülmektedir. Bu çalışmanın amacı; değişik evrelerdeki kronik karaciğer hastalarında plazma nitrik oksit, nitrik oksit sentetaz düzeyleri ve renal fonksiyonlar arasındaki ilişkiyi değerlendirmektir. Yöntem: Çalışma grubundaki 38 hastanın 14’ü kronik hepatit, 11’i preasitik siroz ve 13’ü asitik sirozlu hasta idi. Nitrik oksit, nitrik oksit sentetaz kolorimetrik yöntemle çalışıldı. Glomerüler filtrasyon hızı ve fraksiyonel sodyum atılımlarını hesapladık. Bulgular: Nitrik oksit seviyeleri gruplarda sırası ile; 79.28±24.86, 99.03±21.31, 197.05±49.61µm idi. Nitrik oksit sentetaz seviyeleri ise; 2.64±0.56, 3.64±0.89, 7.75±2.46 mol/1/dk idi. Nitrik oksit, nitrik oksit sentetaz seviyeleri asitik sirozlu grupta diğer gruplara göre anlamlı ölçüde yüksekti (P<0.05). Glomerüler filtrasyon hızları karşılaştırıldığında sadece kronik hepatitli ve asitik sirozlu gruplar arasındaki fark anlamlı idi (92.31 ± 25.21, 48.46 ± 16.45, P < 0.08). Fraksiyonel sodyum atılımı asitik sirozlu grupta anlamlı ölçüde artmıştı (4.42±2.76, P<0.05). Sonuç: Nitrik oksit ve nitrik oksit sentetaz karaciğer hastalığının progresyonu ile özellikle asitik sirozlu hastalarda arttı. Aynı zamanda bu artışın renal tubular ve glomerüler fonksiyonları negatif yönde etkilediğini gösterdik.

🔖

Cite This Article

TÜRKAY, C., YÖNEM, N. Ö. S., ARIKAN, O., BASKIN, S. E. (2004). Karaciğer sirozunda nitrik oksit ve renal fonksiyonlar. Turkish Journal of Gastroenterology, Cilt: 15 - Sayı: 2, 73–76. https://ajindex.com/articles/411202

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Arroyo V, Gines P, Jimenes V, Rodos J. Renal dysfunction in cirrhosis. In: Me Intyre N, Benemou JP, Rhodes J, eds. Oxford Textbook of Clinical Hepatology 1999; 733-61
  2. Schrier RW, Arroyo V, Bernardi M, et al. Peripheral arte rial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 8: 1151-7
  3. Martin P-Y, Gines P, Schrier RW. Nitric oxide as a medi ator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med 1998; 339: 533-40
  4. Barak N, Zemel R, Ben-an Z, et al. Nitric oxide metabolites in decompensated liver cirrhosis. Dig Dis Scie 1999; 44: 1338-41
  5. Martin PY, Ohara M, Gines P, et al. Nitric oxide synthase (NOS) inhibition for one week improves renal sodium and water excretion in cirrhotic rats with ascites. J Clin Invest 1998; 101: 235-42
  6. Morales-Ruiz M, Jimenes W, Perez-sala D, et al. Increased nitric oxide synthase expression in arterial vessels of cirr hotic rats with ascites. Hepatology 1996; 24: 1481-6
  7. Robert LR, Kamath PS. Ascites and hepatorenal syndrome: pathophysiology and management. Mayo Clin Pro 1996; 71: 874-81
  8. Arroyo V, Guevara M, Gines P. Hepatorenal syndrome in cirrhosis. Pathogenesis and treatment. Gastroenterology 2002; 122: 1658-76
  9. Arroyo V, Jimenez W. Complications of cirrhosis. II Renal and circulatory dysfunction. Lights and shadows in an im portant clinical problem. J Hepatology 2000; 32: 157-70
  10. Danovitch GM, Wilkinson AH. Evaluation of renal functi on. In: Massry SG, Glassock RJ, eds. Textbook of Nephro logy, 4th edition, Vol 2. Baltimore: Williams&Wilkins, 1995; 1620-7
  11. Kramer L, Hori WH. Hepatorenal syndrome. Semin Neph rol 2002; 22: 290-301
  12. Gines A, Escorsell A, Gines P, et al. Incidence, predictive factors and prognosis of the hepatorenal syndrome in cirr hosis with ascites. Gastroenterology 1993; 109: 229-236
  13. Wong F, Blendis L. New challenge of hepatorenal syndro me: prevention and treatment. Hepatology 2001; 34: 1242- 51
  14. Garcia-Estan J, Atucha NM, Sabio JM, et al. Increased en- dothelium-dependent renal vasodilation in cirrhotic rats. Am J Physiol 1994; 267: 549-53
  15. Arroyo V, Gines P, Gerbes A, et al. Definition and diagnos tic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996; 23: 164-76
  16. Dudley FJ, Kanel GC, Wood LJ, Reynolds TB. Hepatorenal syndrome without avid sodium retention. Hepatology 1986; 6: 248-51
  17. Rector WG, Kanel